Global Regulatory Strategy

Top Tips for Your Global Regulatory Strategy

By Maria Fontanazza
No Comments
Global Regulatory Strategy

Industry experts share advice that could influence company success.

Last week MedTech Intelligence invited global regulatory experts to gather and educate the industry about the tactics they use to build, evaluate and coordinate an effective regulatory strategy that addresses the ever-changing international environment. Here’s what these senior leaders had to say.

Michael Morton, Medtronic, Global Regulatory Strategy
Michael Morton, Medtronic

On the core elements of an effective global regulatory strategy

“There can be inefficiencies due to differing assumptions between groups. If there’s a misalignment, you’re going to miss overall what you’re trying to do. Understanding cross-functional considerations is critical.” – Michael Morton, vice president, corporate regulatory affairs, Medtronic

“The value of the regulatory strategy: Helping the commercial team have an understanding of what they can do and how to achieve it.” – Sergio Gadaleta, senior vice president, regulatory affairs, BD

“What’s the most important non-regulatory quality for a regulatory person to have? Being an effective communicator.”  – Tony Blank, co-founder & senior advisor, Barton & Blank

Susan Alpert, SFA Consulting, Global Regulatory Strategy
Susan Alpert, SFA Consulting

On aligning regulatory strategy and market considerations

“Understand how medicine is practiced in the areas you’re going to. That’s an important consideration. Who are the users? Who are the patients? In what geographies are these important diseases? One of the mistakes many companies make is to decide [where they’re going to distribute products] without thinking about to whom, for whom and under what conditions. What kind of hospital environment is required? And does that even exist there?”  – Susan Alpert, principal, SFA Consulting

“Global regulations are rapidly changing. It’s hard to get the information [and] hard to get the intelligence. Sometimes we have to get it from each other.” – Nicole Taylor Smith, senior director, global regulatory affairs policy and intelligence, Johnson & Johnson

Global Regulatory Strategy
(left to right) Matthew Hein, U.S. Department of Commerce, Nicole Taylor Smith, Johnson & Johnson and Peter Havel, TUV SUD

“[There will be fewer] resources for notified bodies. Start now with your notified body— show your concept and start to talk about the requirements, [and] understand the consequences of your product portfolio (know which products to phase out and which to move forward with). – Peter Havel, TUV SUD

On best practices and leadership skills

“Communication. I don’t think you can over-communicate anything; understanding the message and the strategy, and the limiting factors we have to consider.” – Michael Santalucia, vice president, global regulatory affairs, TerumoBCT

About The Author

Maria Fontanazza, MedTech Intelligence

Leave a Reply

Your email address will not be published. Required fields are marked *

For security, use of Google's reCAPTCHA service is required which is subject to the Google Privacy Policy and Terms of Use.

I agree to these terms.